IN2014DN05759A - - Google Patents

Info

Publication number
IN2014DN05759A
IN2014DN05759A IN5759DEN2014A IN2014DN05759A IN 2014DN05759 A IN2014DN05759 A IN 2014DN05759A IN 5759DEN2014 A IN5759DEN2014 A IN 5759DEN2014A IN 2014DN05759 A IN2014DN05759 A IN 2014DN05759A
Authority
IN
India
Prior art keywords
control
basification
hcv
viral
formation
Prior art date
Application number
Other languages
English (en)
Inventor
Mathias Braun
Carl Alan Busacca
feng jing Chen
Edwin Louis Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN05759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2014DN05759A publication Critical patent/IN2014DN05759A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5759DEN2014 2012-01-12 2013-01-10 IN2014DN05759A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
PCT/US2013/020934 WO2013106506A1 (fr) 2012-01-12 2013-01-10 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Publications (1)

Publication Number Publication Date
IN2014DN05759A true IN2014DN05759A (fr) 2015-04-10

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5759DEN2014 IN2014DN05759A (fr) 2012-01-12 2013-01-10

Country Status (27)

Country Link
US (2) US20140037719A1 (fr)
EP (1) EP2802313A1 (fr)
JP (1) JP2015503616A (fr)
KR (1) KR20140109433A (fr)
CN (1) CN104244926A (fr)
AP (1) AP2014007760A0 (fr)
AR (1) AR089710A1 (fr)
AU (1) AU2013208024A1 (fr)
BR (1) BR112014017058A8 (fr)
CA (1) CA2861041A1 (fr)
CL (1) CL2014001783A1 (fr)
CO (1) CO7000774A2 (fr)
EA (1) EA201400808A1 (fr)
EC (1) ECSP14013104A (fr)
HK (1) HK1204982A1 (fr)
IL (1) IL233550A0 (fr)
IN (1) IN2014DN05759A (fr)
MA (1) MA35865B1 (fr)
MX (1) MX2014008205A (fr)
NZ (1) NZ626353A (fr)
PE (1) PE20141817A1 (fr)
PH (1) PH12014501598A1 (fr)
SG (1) SG11201404042VA (fr)
TN (1) TN2014000295A1 (fr)
TW (1) TW201340969A (fr)
UY (1) UY34569A (fr)
WO (1) WO2013106506A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
SG11201507223TA (en) 2013-03-15 2015-10-29 Gilead Sciences Inc Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
JP5156374B2 (ja) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 非環式hcvプロテアーゼインヒビターの調製方法
WO2006130552A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
EP2687526A1 (fr) 2008-09-16 2014-01-22 Boehringer Ingelheim International Gmbh Formes cristallines d'un derive de 2-thiazolyl- 4-quinolinyl-oxy, un inhibiteur puissant du VHC
CA2738732A1 (fr) 2008-11-21 2010-05-27 Boehringer Ingelheim International Gmbh Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
ME01718B (me) * 2009-07-07 2014-09-20 Boehringer Ingelheim Int Farmaceutska kompozicija za inhibitor proteaze virusnog Hepatitis C

Also Published As

Publication number Publication date
IL233550A0 (en) 2014-08-31
EA201400808A1 (ru) 2015-02-27
US20140037719A1 (en) 2014-02-06
SG11201404042VA (en) 2014-08-28
CN104244926A (zh) 2014-12-24
MX2014008205A (es) 2014-08-08
EP2802313A1 (fr) 2014-11-19
MA35865B1 (fr) 2014-12-01
PH12014501598A1 (en) 2014-10-08
TW201340969A (zh) 2013-10-16
KR20140109433A (ko) 2014-09-15
ECSP14013104A (es) 2015-11-30
TN2014000295A1 (en) 2015-12-21
PE20141817A1 (es) 2014-12-17
JP2015503616A (ja) 2015-02-02
UY34569A (es) 2013-07-31
AP2014007760A0 (en) 2014-07-31
WO2013106506A1 (fr) 2013-07-18
AR089710A1 (es) 2014-09-10
CA2861041A1 (fr) 2013-07-18
HK1204982A1 (en) 2015-12-11
US20150190458A1 (en) 2015-07-09
CL2014001783A1 (es) 2014-12-12
AU2013208024A1 (en) 2014-07-10
BR112014017058A8 (pt) 2017-07-04
CO7000774A2 (es) 2014-07-21
BR112014017058A2 (pt) 2017-06-13
NZ626353A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
MX2018013668A (es) Inhibidores de virus de hapatitis c.
PL3224254T3 (pl) Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
WO2012040389A3 (fr) Inhibiteurs bicycliques substitués du virus de l'hépatite c
DK2801611T3 (da) Mikroorganisme, der kan producere l-aminosyre, og fremgangsmåde til fremstilling af l-aminosyre ved brug af samme
HK1205743A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments 3--135(10)16-
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
NZ728401A (en) High purity oritavancin and method of producing same
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
IN2014DN05759A (fr)
PT3244744T (pt) Material para o despoeiramento de preparações enzimáticas granulares
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
WO2014159501A3 (fr) Procédés de préparation de tetrahydroisoquinoleines
HK1243712A1 (zh) 作為用於治療丙型肝炎的hcv抑制劑的核苷酸衍生物
SG11201610453SA (en) Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof
EP3065737A4 (fr) Forme pharmaceutique à usage oral pour prévenir les maladies vasculaires, comprimé et capsule en gélatine à titre de forme pharmaceutique
IN2014MU00077A (fr)
HUP1300648A2 (hu) Dabigatran és származékainak komplexei,elõállításuk és gyógyszerészeti kompozícióik
IN2014MU00076A (fr)
MX2015003954A (es) Composicion farmaceutica de liberacion controlada en tres pulsos dependientes de ph de betahistina.
MY185444A (en) Enterovirus 71 antiviral peptides
TH1301000018B (th) รูปผลึกเดลตาของเกลืออาร์จินีน (arginine) ของเพอรินโดพริล (perindopril), กระบวนการสำหรับการเตรียมสารดังกล่าว และองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว
TH154809A (th) สูตรผสมทางเภสัชกรรมคงสภาพของสารยับยั้ง hcv ที่มีฤทธิ์แรง